Tesamorelin 5MG

Tesamorelin peptide Canada: a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of 44 amino acids with a trans-3-hexenoic acid modification at the N-terminus. Available from Maple Research Labs at 5mg per vial with greater than 98% HPLC-verified purity and batch-specific COA.

Product Specifications

• CAS Number: 218949-48-5
• Structure: Modified GHRH(1-44) analog
• Molecular Weight: Approximately 5135 Da
• Purity: >98% (HPLC verified)
• Form: Lyophilized powder
• Quantity: 5mg per vial

Tesamorelin Peptide Canada Research Summary

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog that stimulates the anterior pituitary to produce and release growth hormone through the GHRH receptor pathway. The tesamorelin peptide Canada product features the characteristic trans-3-hexenoic acid modification at the tyrosine-1 position, which confers increased resistance to enzymatic degradation compared to native GHRH(1-44).

Unlike direct growth hormone secretagogues that act on the GHSR (ghrelin receptor), tesamorelin operates through the GHRH receptor, stimulating physiological pulsatile GH release patterns. This distinction in mechanism is significant for neuroendocrine research, as GHRH-mediated and ghrelin-mediated GH release involve different signaling cascades and feedback mechanisms.

Mechanism of Action Research

Tesamorelin binds to the GHRH receptor (GHRHR) on somatotroph cells in the anterior pituitary gland. Receptor activation triggers adenylyl cyclase signaling, elevating intracellular cAMP levels and ultimately leading to GH gene transcription, synthesis, and secretion. This pathway maintains the physiological pulsatile pattern of GH release, in contrast to exogenous GH administration which provides continuous non-pulsatile delivery.

The N-terminal hexenoic acid modification protects tesamorelin from dipeptidyl peptidase IV (DPP-IV) cleavage, which rapidly inactivates native GHRH by removing the N-terminal Tyr-Ala dipeptide. This structural modification extends the peptide’s biological half-life while preserving receptor binding affinity and selectivity.

Research has compared tesamorelin to other GHRH analogs including CJC-1295 (with and without DAC modification), examining differences in pharmacokinetic profiles, GH release patterns, and IGF-1 axis stimulation in animal models. Published studies have characterized the dose-response relationship for GH release and the time course of pituitary stimulation.

Preclinical Study Summary

Tesamorelin has been extensively studied in preclinical and clinical settings, particularly in the context of lipodystrophy research. Published peer-reviewed studies have examined its effects on visceral adipose tissue, lipid metabolism, body composition, and IGF-1 axis regulation. The compound has one of the more substantial clinical evidence bases among GHRH analogs.

All research applications of this product are for laboratory use only. Researchers should consult primary literature for experimental protocols.

References

• Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007 (PubMed)

Tesamorelin Peptide Canada Quality Assurance

Every batch of tesamorelin peptide Canada from Maple Research Labs undergoes independent third-party HPLC analysis confirming purity exceeding 98%. Each order includes a batch-specific COA with retention time data, purity percentage, and mass spectrometry confirmation. The N-terminal hexenoic acid modification requires specific analytical verification, which our third-party laboratory confirms for structural integrity on every production batch.

Storage and Handling

Store lyophilized at -20C. Reconstituted at 2-8C, use within 30 days. Avoid freeze-thaw cycles.

Shipping

Ships same-day from our Canadian facility. Temperature-controlled packaging included.

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.

Related Research Articles

• HGH vs Tesamorelin: Research Comparison
• Ipamorelin vs Tesamorelin: Understanding the Differences
• Certificates of Analysis (COA) Documentation
• Browse All Research Peptides

Frequently Asked Questions

What is the CAS number for Tesamorelin?

The CAS registry number for Tesamorelin is 218949-48-5. It is a synthetic analog of growth hormone-releasing hormone (GHRH).

What is Tesamorelin purity at Maple Research Labs?

Batch MRL-TSM-0326 tested at 98.4% purity by HPLC at Janoshik Analytical.

How should Tesamorelin be stored?

Lyophilized: -20C. Tesamorelin is a 44-amino acid peptide and should be protected from repeated freeze-thaw cycles once reconstituted.